129 related articles for article (PubMed ID: 16971704)
41. Exenatide.
Barnett AH
Drugs Today (Barc); 2005 Sep; 41(9):563-78. PubMed ID: 16341288
[TBL] [Abstract][Full Text] [Related]
42. Novel pharmacologic agents for type 2 diabetes.
Uwaifo GI; Ratner RE
Endocrinol Metab Clin North Am; 2005 Mar; 34(1):155-97. PubMed ID: 15752927
[TBL] [Abstract][Full Text] [Related]
43. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
44. Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.
Syed YY; McCormack PL
Drugs; 2015 Jul; 75(10):1141-52. PubMed ID: 26071140
[TBL] [Abstract][Full Text] [Related]
45. Clinical studies.
Young A
Adv Pharmacol; 2005; 52():289-320. PubMed ID: 16492555
[TBL] [Abstract][Full Text] [Related]
46. Pramlintide in the treatment of diabetes.
Edelman SV; Darsow T; Frias JP
Int J Clin Pract; 2006 Dec; 60(12):1647-53. PubMed ID: 17109671
[TBL] [Abstract][Full Text] [Related]
47. New drugs for type 2 diabetes mellitus: what is their place in therapy?
Krentz AJ; Patel MB; Bailey CJ
Drugs; 2008; 68(15):2131-62. PubMed ID: 18840004
[TBL] [Abstract][Full Text] [Related]
48. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.
Parkes DG; Mace KF; Trautmann ME
Expert Opin Drug Discov; 2013 Feb; 8(2):219-44. PubMed ID: 23231438
[TBL] [Abstract][Full Text] [Related]
49. Type 2 diabetes: the many facets of care.
Hall MA
Home Healthc Nurse; 2008 Jun; 26(6):346-53; quiz 354-5. PubMed ID: 18562819
[TBL] [Abstract][Full Text] [Related]
50. Exenatide: a novel approach for treatment of type 2 diabetes.
Mikhail N
South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423
[TBL] [Abstract][Full Text] [Related]
51. A gut feeling.
Pronsati MP
Adv Nurse Pract; 2004 Aug; 12(8):8. PubMed ID: 15354498
[No Abstract] [Full Text] [Related]
52. A look back at the most influential drug approvals of 2005.
Laustsen G; Gilbert M; Wimett L
Nurse Pract; 2006 Feb; 31(2):26, 29-36, 41; quiz 42-3. PubMed ID: 16452899
[No Abstract] [Full Text] [Related]
53. Exenatide and biotin in conjunction with a protein-sparing fast for normalization of beta cell function in type 2 diabetics.
McCarty MF
Med Hypotheses; 2007; 69(4):928-32. PubMed ID: 17292559
[TBL] [Abstract][Full Text] [Related]
54. [Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014; 143 Suppl 2():23-7. PubMed ID: 25326840
[TBL] [Abstract][Full Text] [Related]
55. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
Camafort-Babkowski M
Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
[TBL] [Abstract][Full Text] [Related]
56. Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi S; Nayak AK; Behera A
Biomed Pharmacother; 2020 Nov; 131():110708. PubMed ID: 32927252
[TBL] [Abstract][Full Text] [Related]
57. Amylin's pramlintide best of bad bunch of diabetes drugs.
Brower V
Nat Biotechnol; 1997 Oct; 15(10):935. PubMed ID: 9335036
[No Abstract] [Full Text] [Related]
58. New drugs 06, part I.
Hussar DA
Nursing; 2006 Feb; 36(2):54-61; quiz 62-3. PubMed ID: 16462265
[No Abstract] [Full Text] [Related]
59. CE: Type 2 Diabetes: A Pharmacologic Update.
Keresztes P; Peacock-Johnson A
Am J Nurs; 2019 Mar; 119(3):32-40. PubMed ID: 30741763
[TBL] [Abstract][Full Text] [Related]
60. Practical considerations of new drugs: new choices for old problems.
Frank T
Consult Pharm; 2006 Apr; 21(4):276-8, 281-83. PubMed ID: 16669748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
